title: Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.
abstract: Rapid immune recognition and subsequent elimination from the circulation hampers the use of many nanomaterials as carriers to targeted drug delivery and controlled release in the intravenous route. Here, we report the effect of a functional self-assembled protein coating on the intravenous biodistribution of (18)F-labeled thermally hydrocarbonized porous silicon (THCPSi) nanoparticles in rats. (18)F-Radiolabeling enables the sensitive and easy quantification of nanoparticles in tissues using radiometric methods and allows imaging of the nanoparticle biodistribution with positron emission tomography. Coating with Trichoderma reesei HFBII altered the hydrophobicity of (18)F-THCPSi nanoparticles and resulted in a pronounced change in the degree of plasma protein adsorption to the nanoparticle surface in vitro. The HFBII-THCPSi nanoparticles were biocompatible in RAW 264.7 macrophages and HepG2 liver cells making their intravenous administration feasible. In vivo, the distribution of the nanoparticles between the liver and spleen, the major mononuclear phagocyte system organs in the body, was altered compared to that of uncoated (18)F-THCPSi. Identification of the adsorbed proteins revealed that certain opsonins and apolipoproteins are enriched in HFBII-functionalized nanoparticles, whereas the adsorption of abundant plasma components such as serum albumin and fibrinogen is decreased.
authors.affiliation: Laboratory of Radiochemistry, Department of Chemistry, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland. mirkka.sarparanta@helsinki.fi
authors.forename: Mirkka
authors.initials: M
authors.lastname: Sarparanta
authors.forename: Luis M
authors.initials: LM
authors.lastname: Bimbo
authors.forename: Jussi
authors.initials: J
authors.lastname: Rytkönen
authors.forename: Ermei
authors.initials: E
authors.lastname: Mäkilä
authors.forename: Timo J
authors.initials: TJ
authors.lastname: Laaksonen
authors.forename: Päivi
authors.initials: P
authors.lastname: Laaksonen
authors.forename: Markus
authors.initials: M
authors.lastname: Nyman
authors.forename: Jarno
authors.initials: J
authors.lastname: Salonen
authors.forename: Markus B
authors.initials: MB
authors.lastname: Linder
authors.forename: Jouni
authors.initials: J
authors.lastname: Hirvonen
authors.forename: Hélder A
authors.initials: HA
authors.lastname: Santos
authors.forename: Anu J
authors.initials: AJ
authors.lastname: Airaksinen
mesh_terms: D000327:Adsorption; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism*; D002460:Cell Line; D004355:Drug Stability; D056945:Hep G2 Cells; D006801:Humans; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry*; D016062:Porosity; D012825:Silicon / Q000737:chemistry*
chemical_list: D001798:Blood Proteins; D012825:Silicon